Core Viewpoint - Samsung Medical has been recognized as a candidate for a major procurement project by the State Grid Corporation of China, with an expected total bid amount of approximately 168 million yuan, which will strengthen its position in the domestic power grid market and drive annual performance growth [1][2]. Group 1: Recent Achievements - Samsung Medical's subsidiary, Aixs Intelligent Technology, has been recommended as a candidate for a procurement project that includes key electrical equipment such as overhead insulated wires and 10KV transformers [1][2]. - Since 2025, Samsung Medical has secured significant orders, with a total order backlog of 17.914 billion yuan as of the end of the third quarter of 2025, representing a year-on-year increase of 14.69% [1][2]. Group 2: Financial Performance - The company reported revenues of 9.098 billion yuan, 11.46 billion yuan, and 14.6 billion yuan for the years 2022 to 2024, with year-on-year growth rates of 29.55%, 25.99%, and 27.38% respectively [4][5]. - In the first three quarters of 2025, the company achieved revenue of 11.08 billion yuan, a year-on-year increase of 6.19%, but the net profit attributable to shareholders decreased by 15.85% to 1.528 billion yuan [5]. Group 3: Research and Development - Samsung Medical has invested heavily in R&D, with total R&D expenses exceeding 2.037 billion yuan over the past five years, which has strengthened its technological capabilities and product competitiveness [4][6]. - The company has received 32 automation patents in the last three years and is advancing its "smart manufacturing" strategy, including the establishment of the industry's first digital factory [6].
三星医疗预中标1.68亿国网项目 近5年研发费超20亿推动产品升级